Modulation of estrogen receptor α protein level and survival function by DBC-1

Molecular Endocrinology

Volumn 21, Issue 7, 2007, Pages 1526-1536

  Trauernicht, Amy M ^a   Se, Jin Kim ^a   Nam, Hee Kim ^a   Boyer, Thomas G ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; FULVESTRANT; RNA; TAMOXIFEN;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; GENE DELETION; GENE DISRUPTION; GENE FUNCTION; GENE IDENTIFICATION; HORMONAL THERAPY; HORMONE BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RNA INTERFERENCE; STEADY STATE;

BASE SEQUENCE; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DNA PRIMERS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; FEMALE; HELA CELLS; HUMANS; LIGANDS; NEOPLASM PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEINS;

EID: 34347221253     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2007-0064     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ 2006 Cancer statistics, 2006. CA Cancer J Clin 56:106-130
2. Hilakivi-Clarke L, Cho E, Cabanes A, DeAssis S, Olivo S, Helferich W, Lippman ME, Clarke R 2002 Dietary modulation of pregnancy estrogen levels and breast cancer risk among female rat offspring. Clin Cancer Res 8:3601-3610
3. Koibuchi Y, Sugamata N, Iino Y, Yokoe T, Andoh T, Maemura M, Takei H, Horiguchi J, Matsumoto H, Morishita Y 1999 The mechanisms of antitumor effects of luteinizing hormone-releasing hormone agonist (buserelin) in 7, 12-dimethylbenz(a)anthracene-induced rat mammary cancer. Int J Mol Med 4:145-148
4. Liao DZ, Pantazis CG, Hou X, Li SA 1998 Promotion of estrogen-induced mammary gland carcinogenesis by androgen in the male Noble rat: probable mediation by steroid receptors. Carcinogenesis 19:2173-2180
5. Couse JF, Korach KS 1999 Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 20:358-417
6. McDonnell DP, Norris JD 2002 Connections and regulation of the human estrogen receptor. Science 296:1642-1644
7. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA 2001 Mechanisms of estrogen action. Physiol Rev 81:1535-1565
8. Osborne CK, Schiff R 2005 Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 23:1616-1622
9. Clarke RB, Anderson E, Howell A 2004 Steroid receptors in human breast cancer. Trends Endocrinol Metab 15:316-323
10. Ali S, Coombes RC 2000 Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia 5:271-281
11. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE 2004 Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96:218-228
12. Key TJ, Verkasalo PK, Banks E 2001 Epidemiology of breast cancer. Lancet Oncol 2:133-140
13. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC 2005 The NFκB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 12(Suppl 1):S37-S46
14. Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A, Perrone F 2005 Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 12:721-747
15. Huang J, Li X, Hilf R, Bambara RA, Muyan M 2005 Molecular basis of therapeutic strategies for breast cancer. Curr Drug Targets Immune Endocr Metabol Disord 5:379-396
16. Rau KM, Kang HY, Cha TL, Miller SA, Hung MC 2005 The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Relat Cancer 12:511-532
17. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK 2004 Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10:331S-336S
18. Hamaguchi M, Meth JL, von Klitzing C, Wei W, Esposito D, Rodgers L, Walsh T, Welcsh P, King MC, Wigler MH 2002 DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci USA 99:13647-13652
19. Radvanyi L, Singh-Sandhu D, Gallichan S, Lovitt C, Pedyczak A, Mallo G, Gish K, Kwok K, Hanna W, Zubovits J, Armes J, Venter D, Hakimi J, Shortreed J, Donovan M, Parrington M, Dunn P, Oomen R, Tartaglia J, Berinstein NL 2005 The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc Natl Acad Sci USA 102:11005-11010
20. Bittner M 2005 A window on the dynamics of biological switches. Nat Biotechnol 23:183-184
21. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R 2002 A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009
22. Zhao H, Langerod A, Ji Y, Nowels KW, Nesland JM, Tibshirani R, Bukholm IK, Karesen R, Botstein D, Borresen-Dale AL, Jeffrey SS 2004 Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 15:2523-2536
23. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S 2006 X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9:121-132
24. Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K, Cruciat C, Eberhard D, Gagneur J, Ghidelli S, Hopf C, Huhse B, Mangano R, Michon AM, Schirle M, Schlegl J, Schwab M, Stein MA, Bauer A, Casari G, Drewes G, Gavin AC, Jackson DB, Joberty G, Neubauer G, Rick J, Kuster B, Superti-Furga G 2004 A physical and functional map of the human TNF-α/NF-κB signal transduction pathway. Nat Cell Biol 6:97-105
25. Sundararajan R, Chen G, Mukherjee C, White E 2005 Caspase-dependent processing activates the proapoptotic activity of deleted in breast cancer-1 during tumor necrosis factor-α-mediated death signaling. Oncogene 24:4908-4920
26. Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L 2001 Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res 7:2076-2084
27. Fliss AE, Benzeno S, Rao J, Caplan AJ 2000 Control of estrogen receptor ligand binding by Hsp90. J Steroid Biochem Mol Biol 72:223-230
28. Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J, Gannon F 2003 Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11:695-707
29. Jordan VC 2004 Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 5:207-213
30. Riggins RB, Bouton AH, Liu MC, Clarke R 2005 Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam Horm 71:201-237
31. Howell A 2006 Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr Relat Cancer 13:689-706
32. Fanelli MA, Vargas-Roig LM, Gago FE, Tello O, Lucero De Angelis R, Ciocca DR 1996 Estrogen receptors, progesterone receptors, and cell proliferation in human breast cancer. Breast Cancer Res Treat 37:217-228
33. Sommer S, Fuqua SA 2001 Estrogen receptor and breast cancer. Semin Cancer Biol 11:339-352
34. Lee MO, Kim EO, Kwon HJ, Kim YM, Kang HJ, Kang H, Lee JE 2002 Radicicol represses the transcriptional function of the estrogen receptor by suppressing the stabilization of the receptor by heat shock protein 90. Mol Cell Endocrinol 188:47-54
35. Pratt WB, Toft DO 1997 Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18:306-360
36. Zhou Y, Eppenberger-Castori S, Marx C, Yau C, Scott GK, Eppenberger U, Benz CC 2005 Activation of nuclear factor-κB (NFκB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol 37:1130-1144
37. Bhat-Nakshatri P, Sweeney CJ, Nakshatri H 2002 Identification of signal transduction pathways involved in constitutive NF-κB activation in breast cancer cells. Oncogene 21:2066-2078
38. deGraffenried LA, Chandrasekar B, Friedrichs WE, Donzis E, Silva J, Hidalgo M, Freeman JW, Weiss GR 2004 NF-κB inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 15:885-890
39. Pratt MA, Bishop TE, White D, Yasvinski G, Menard M, Niu MY, Clarke R 2003 Estrogen withdrawal-induced NF-κB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. Mol Cell Biol 23:6887-6900
40. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ, Sledge Jr GW 1997 Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629-3639
41. Mandlekar S, Kong AN 2001 Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6:469-477
42. Dowsett M, Archer C, Assersohn L, Gregory RK, Ellis PA, Salter J, Chang J, Mainwaring P, Boeddinghaus I, Johnston SR, Powles TJ, Smith IE 1999 Clinical studies of apoptosis and proliferation in breast cancer. Endocr Relat Cancer 6:25-28
43. Liu JW, Picard D 1998 Bioactive steroids as contaminants of the common carbon source galactose. FEMS Microbiol Lett 159:167-171
44. Turner DL, Weintraub H 1994 Expression of achaetescute homolog 3 in Xenopus embryos converts ectodermal cells to a neural fate. Genes Dev 8:1434-1447
45. Qi C, Chang J, Zhu Y, Yeldandi AV, Rao SM, Zhu YJ 2002 Identification of protein arginine methyltransferase 2 as a coactivator for estrogen receptor α. J Biol Chem 277:28624-28630
46. Ignar-Trowbridge DM, Teng CT, Ross KA, Parker MG, Korach KS, McLachlan JA 1993 Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol Endocrinol 7:992-998
47. Zheng L, Annab LA, Afshari CA, Lee WH, Boyer TG 2001 BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci USA 98:9587-9592
48. Dignam JD, Lebovitz RM, Roeder RG 1983 Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11:1475-1489